
ARTHEx Biotech Reports Brain Function Recovery in DM1 Model
A preclinical study published in Cell Reports Medicine confirms that the investigational therapy ATX-01 can cross the blood-brain barrier, correcting molecular defects and improving behavioral patterns in subjects with myotonic dystrophy type 1. This marks the first evidence linking systemic RNA-based treatment to neurological restoration in DM1.







/paternoster-square-136108254-5e089d0e1b404273ad15513a01e07c7c.jpg)


















